The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description

Louise M. Paterson(Imperial College London), Eleanor Taylor(University of Manchester), J.F.W. Deakin(University of Manchester), Rebecca Elliott(University of Manchester), Emilio Fernández-Egea(University of Cambridge), Karen D. Ersche(University of Cambridge), John Suckling(University of Cambridge), Luca Faravelli(Imperial College London), Csaba Orbán(Imperial College London), Yetunde O. Faluyi(Cambridgeshire and Peterborough NHS Foundation Trust), Remy Flechais(Imperial College London), David Erritzøe(Imperial College London), Inge Mick(Imperial College London), Anna Murphy(University of Manchester), Nicola J. Kalk(King's College London), Venkataramana Boyapati(University of Manchester), Shankar Kuchibatla(University of Manchester), Roger Tait(University of Cambridge), Adam Waldman(Royal Society of Edinburgh), Liam J. Nestor(GlaxoSmithKline (United Kingdom)), Antonio Metastasio(University of Manchester), Sanja Abbott(University of Cambridge), Anne Lingford‐Hughes(Hammersmith Hospital), Trevor W. Robbins(University of Cambridge), Filippo Passetti(University of Cambridge), John McGonigle(Imperial College London), Laurence Reed(Imperial College London), Dana Smith(University of Cambridge), Eugenii A. Rabiner(GlaxoSmithKline (United Kingdom)), David Nutt(Imperial College London)

Journal of Psychopharmacology

August 5, 2015

Cited by 36

|Journal of Neuroscience|2006|2.5k

|Cerebral Cortex|2005|1.4k

|Nature Reviews Drug Discovery|2012|1.3k

|Neuroscience & Biobehavioral Reviews|2014|1.2k

|Annual Review of Psychology|2015|1.2k

Related Papers